Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

This study aimed to compare the efficacy of nimotuzumab (Nimo) versus cetuximab (C225) plus concurrent chemoradiotherapy (CCRT) in locally advanced esophageal squamous cell carcinoma (LA-ESCC). A total of 95 patients with LA-ESCC were retrospectively reviewed, including 65 in Nimo and 30 in C225. Th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Jing, Wang, Yan, Weiwei, Liu, Yuguo, Li, Ji, Yu, Jinming, Zhu, Hui
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606014/
https://ncbi.nlm.nih.gov/pubmed/30983494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1598760
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars